Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

BRIDGEWATER, NJ / ACCESSWIRE / July 10, 2024 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company, announces the appointment of Jules Haimovitz as a Strategic Advisor. Haimovitz will join the executive management team, bringing decades of biotechnology leadership.

"We are pleased to have Jules join Tharimmune," stated Randy Milby, CEO of Tharimmune. "His extensive success in the biotechnology industry and strategic acumen will bolster our clinical and preclinical programs. His experience will be instrumental in setting and navigating the optimal strategy for our pipeline."

Haimovitz has served on the Boards of several prominent companies. His expertise in corporate governance and strategic planning is expected to augment Tharimmune's efforts in innovative treatments. His role will be particularly valuable for the Phase 2 program for TH104, targeting pruritus in patients with primary biliary cholangitis (PBC).

Haimovitz expressed enthusiasm for his new role, emphasizing the critical importance of Phase 2 testing for biopharmaceutical companies. He looks forward to applying his experience to support Tharimmune effectively during this phase.